ÂÜÀòÂÒÂ×

Dr. Glick is a chemist and serial biotech entrepreneur with over 15 years’ experience in the biotech industry. He has founded several successful companies, including IFM Therapeutics. While CEO of IFM, the company progressed three programs from ideation to clinical development and executed several major transactions, including the sale of oncology assets to Bristol-Myers Squibb in a transaction valued more than $2.3 billion and the sale of an NLRP3 inhibitor program to Novartis for $1.6 billion. Prior to Odyssey, in 2020, he co-founded and launched Scorpion Therapeutics, where he played an instrumental role in the conception and building of the company. During his tenure as CEO, Scorpion grew to nearly 50 employees and raised $270 million across two financings. He is the author of more than 100 papers, the inventor on 54 issued U.S. patents, and the recipient of numerous awards recognizing his scientific contributions and accomplishments as a life science executive. Dr. Glick received his Ph.D. in Organic Chemistry from Columbia University and completed an NIH postdoctoral fellowship in Organic Chemistry at Harvard University.